Antiestrogenic treatment of advanced and recurrent carcinoma corporis uteri--a phase II study of toremifene.
The antitumor efficacy and toxicity of a new anti-estrogenic substance--toremifene--were investigated in a phase II study. Twenty-six patients were eligible for final evaluation (6 primary and 20 recurrent disease). A daily dose of 200 mg toremifene was given orally. Treatment continued for at least 3 months, until progression or significant side-effects were encountered. The response rate was 35% (3 CR and 6 PR). Six patients had NC and 11 did not respond to the treatment. The median duration of responses for CR was 10+ months (range 3(+)-19) and for PR 4 months (range 3(+)-16). The treatment seems to be well tolerated and effective.
Horvath
G
G
Department of Oncology, University Hospital, Lund, Sweden.
Stendahl
U
U
Kalling
M
M
Fernö
M
M
Himmelmann
A
A
Hajba
A
A
D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009367:Neoplasm Staging; D013629:Tamoxifen / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017312:Toremifene; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology
D004965:Estrogen Antagonists; D013629:Tamoxifen; D017312:Toremifene